Partial response or better at six months is prognostic of superior progression-free survival in WM patients treated with Ibrutinib

Jorge J. Castillo, Jithma P. Abeykoon, Joshua N. Gustine, Saurabh Zanwar, Kirsten Mein, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nickolas Tsakmaklis, Rebecca King, Guang Yang, Zachary R. Hunter, Ranjana H. Advani, Maria Lia Palomba, Stephen M. Ansell, Morie A. Gertz, Prashant Kapoor and Steven P. Treon

Partial response or better at six months is prognostic of superior progression-free survival in WM patients treated with Ibrutinib

British Society for Haematology doi: 10.1111/bjh.17225